siRNA knockdown of NFE2L2, CEBPB and BCL3 in LPS infected THP-1 derived macrophage cell line attenuates macrophages polarizing to C11 state (M1).
(A) Schema describing the experimental design for testing the role of the 3-gene set NCB, predicted to be a switching factor combination between M1 and M2 destinations. The LPS and IL4 treatment conditions are included to verify the experimental setup. The non-targeting siRNA is used as a negative control while siSTAT4 is used as a positive control. siNCB is a knock-down of the 3-gene set (NCB) which is evaluated in this study. (B) Gene expression changes of selected RFs and known markers of M1 (IL1B) and M2 (IL10) in THP1 cell lines upon LPS and IL4 treatment (for 72 hr) respectively. Color coding scheme is similar to that in (A). THP1 monocytes were treated with PMA (20ng/ml) for 16h. Post 24h, LPS (100ng/ml) and IL-4(1000IU) treatment was given for 72 hr. Two-way ANOVA ( P > 0.05 :ns, P < 0.05:*, P < 0.01:**, P < 0.001:*** ; N=3) is used for estimating significance in gene expression fold change. (C) Gene expression changes in the M1 markers upon siRNA knockdown of STAT4 (positive control). THP1 monocytes were treated with PMA (20ng/ml) for 16h. STAT4 specific siRNA was transfected. Post 8h, LPS (100ng/ml) treatment was given for 72h. Gene expression changes in M1 markers were quantified (Two-way ANOVA; P > 0.05 :ns, P < 0.05:*, P < 0.01:**, P < 0.001:*** ; N=3; NT: non-targeting siRNA) (D) Gene expression changes in the M1 and M2 markers upon siRNA knockdown of the NCB set. THP1 monocytes were treated with PMA (20ng/ml) for 16h. NCB (NFE2L2, CEBPB , BCL3) specific siRNA was transfected. Post 8h, LPS (100ng/ml) treatment was given for 72h. Gene expression changes of M1 and M2 markers were quantified (Two-way ANOVA; P > 0.05 :ns, P < 0.05:*, P < 0.01:**, P < 0.001:*** ; N=3; NT: non-targeting siRNA)